# Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema

> **NCT02245516** · NA · COMPLETED · sponsor: **Kala Pharmaceuticals, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Retinal Vein Occlusion
- Diabetic Macular Edema

## Interventions

- **DRUG:** KPI-121 0.25% Ophthalmic Suspension
- **DRUG:** KPI-121 1.0% Ophthalmic Suspension

## Key facts

- **NCT ID:** NCT02245516
- **Lead sponsor:** Kala Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2020-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02245516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02245516, "Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02245516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*